Wenhui Liu Bo Chen Yiping Liu Zhiying Luo Bao Sun Fang Ma
10.3389/fphar.2021.799728
Front Pharmacol
2022 Jan 3;12:799728.
durvalumab immune checkpoint inhibitors immune-related adverse events neurological demyelination lesions small-cell lung cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/35046822/
Case Reports
PMC8762285
35046822
Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
2022